Clinical trial · no report yet · Phase 3
CEVOLUTION
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- NCT07555938 ↗
- Recruiting
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab; Pomalidomide; Dexamethasone; Daratumumab; Elotuzumab; Carfilzomib
- Arms
- Cevostamab + Pomalidomide + Dexamethasone · Experimental
- Standard of Care (SOC) · Active comparator
- Enrollment
- 380 (estimated)
- Primary outcomes
- Minimal Residual Disease (MRD)-Negative Complete Response (CR) Rate
- Progression-Free Survival (PFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Jun 23, 2026
- Primary completion
- Oct 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07555938 · updated Oct 13, 2026